| Recurrent ETNK1 mutations in atypical chronic myeloid leukemia CB Gambacorti-Passerini, C Donadoni, A Parmiani, A Pirola, S Redaelli, ... Blood, The Journal of the American Society of Hematology 125 (3), 499-503, 2015 | 128 | 2015 |
| Activity of second‐generation ALK inhibitors against crizotinib‐resistant mutants in an NPM‐ALK model compared to EML4‐ALK D Fontana, M Ceccon, C Gambacorti‐Passerini, L Mologni Cancer medicine 4 (7), 953-965, 2015 | 93 | 2015 |
| Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK–positive anaplastic large cell lymphoma M Ceccon, L Mologni, G Giudici, R Piazza, A Pirola, D Fontana, ... Molecular Cancer Research 13 (4), 775-783, 2015 | 65 | 2015 |
| ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine D Fontana, M Mauri, R Renso, M Docci, I Crespiatico, LM Røst, M Jang, ... Nature Communications 11 (1), 5938, 2020 | 32 | 2020 |
| Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy E Bossi, A Aroldi, FA Brioschi, C Steidl, S Baretta, R Renso, L Verga, ... American journal of hematology 95 (12), E319-E321, 2020 | 31 | 2020 |
| De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways V Magistroni, M Mauri, D D’Aliberti, C Mezzatesta, I Crespiatico, M Nava, ... haematologica 104 (9), 1789, 2019 | 24 | 2019 |
| Identification of 4-phenoxyquinoline based inhibitors for L1196M mutant of anaplastic lymphoma kinase by structure-based design S Mah, JH Park, HY Jung, K Ahn, S Choi, HS Tae, KH Jung, JK Rho, ... Journal of medicinal chemistry 60 (22), 9205-9221, 2017 | 21 | 2017 |
| Large-scale analysis of SARS-CoV-2 synonymous mutations reveals the adaptation to the human codon usage during the virus evolution D Ramazzotti, F Angaroni, D Maspero, M Mauri, D D’Aliberti, D Fontana, ... Virus evolution 8 (1), veac026, 2022 | 19 | 2022 |
| Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation E Diral, S Mori, L Antolini, E Abruzzese, P Le Coutre, B Martino, ... Blood, The Journal of the American Society of Hematology 136 (19), 2237-2240, 2020 | 19 | 2020 |
| Integrated genomic, functional, and prognostic characterization of atypical chronic myeloid leukemia D Fontana, D Ramazzotti, A Aroldi, S Redaelli, V Magistroni, A Pirola, ... Hemasphere 4 (6), e497, 2020 | 16 | 2020 |
| Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma G Arosio, GG Sharma, M Villa, M Mauri, I Crespiatico, D Fontana, ... Cancers 13 (17), 4422, 2021 | 13 | 2021 |
| Glomerular filtration rate: A prognostic marker in atrial fibrillation—A subanalysis of the AntiThrombotic Agents Atrial Fibrillation R Proietti, L Gonzini, G Pizzimenti, A Ledda, P Sanna, A AlTurki, V Russo, ... Clinical cardiology 41 (12), 1570-1577, 2018 | 7 | 2018 |
| Molecular pathogenesis of BCR-ABL-negative atypical chronic myeloid leukemia D Fontana, C Gambacorti-Passerini, R Piazza Frontiers in Oncology, 4694, 2021 | 6 | 2021 |
| Myelodysplastic syndromes/myeloproliferative overlap neoplasms and differential diagnosis in the WHO and ICC 2022 era: a focused review D Fontana, EM Elli, F Pagni, R Piazza Cancers 15 (12), 3175, 2023 | 5 | 2023 |
| Impact of ETNK1 somatic mutations on phosphoethanolamine synthesis, ROS production and DNA damage D Fontana, C Gambacorti-Passerini, R Piazza Molecular & Cellular Oncology 8 (2), 1877598, 2021 | 5 | 2021 |
| Drug-resistant NPM/ALK mutants show different sensitivity to second generation tyrosine kinase inhibitors L Mologni, M Ceccon, D Fontana, A Pirola, R Piazza, ... Proceedings of the AACR Annual Meeting, Philadelphia, PA, USA, 18-22, 2015 | 5 | 2015 |
| Evolutionary signatures of human cancers revealed via genomic analysis of over 35,000 patients D Fontana, I Crespiatico, V Crippa, F Malighetti, M Villa, F Angaroni, ... Nature Communications 14 (1), 5982, 2023 | 4 | 2023 |
| RNA‐seq is a valuable complement of conventional diagnostic tools in newly diagnosed AML patients R Piazza, C Cecchetti, A Pirola, C Donandoni, D Fontana, C Mezzatesta, ... American Journal of Hematology 90 (12), E227-E228, 2015 | 4 | 2015 |
| Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia C Gambacorti‐Passerini, FE Nicolini, RA Larson, A Aroldi, D Fontana, ... American Journal of Hematology 97 (8), E296, 2022 | 2 | 2022 |
| Evidence of ETNK1 somatic variants in atypical chronic myeloid leukemia C Donadoni, R Piazza, D Fontana, A Parmiani, A Pirola, S Redaelli, ... Blood 124 (21), 2212, 2014 | 2 | 2014 |
